Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

被引:48
|
作者
Farina, C
Vargas, V
Heydari, N
Kümpfel, T
Meinl, E
Hohlfeld, R
机构
[1] Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany
[2] Univ Munich, Inst Clin Neuroimmunol, D-81366 Munich, Germany
关键词
multiple sclerosis; auto immunity; TH2-lymphocytes;
D O I
10.1016/S0165-5728(01)00490-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We analysed the humoral immune response to glatiramer acetate (GA, Copaxone) in 20 multiple sclerosis patients treated with GA, 20 patients not treated with GA and 20 normal control subjects. Using an ELISA for detection of total GA-reactive immunoglobulins (all isotypes), all treated patients but also 3/20 untreated and 8/20 healthy subjects scored positive at 1:20 plasma dilutions. At higher dilutions, 5/20 treated patients and two healthy donors had relatively high levels of anti-GA antibodies. Isotype and IgG subclass analysis revealed that the two antibody-positive normal subjects had IgM and small titers of IgG1 or IgG2 antibodies. In contrast, 18 of 20 GA-treated patients, had low but significant titers of GA-reactive IgG4 antibodies. This finding is consistent with the previously described GA-mediated induction of T-helper 2 (TH2)-like regulatory T cells. (C) 2002 Elsevier Science B.V All tights reserved.
引用
收藏
页码:188 / 192
页数:5
相关论文
共 50 条
  • [1] Glatiramer acetate for the treatment of multiple sclerosis
    Wolinsky, JS
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (04) : 875 - 891
  • [2] The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment
    Messina, Silvia
    Patti, Francesco
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (10) : 1349 - 1359
  • [3] Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis
    Kornek, B
    Bernert, G
    Balassy, C
    Geldner, J
    Prayer, D
    Feucht, M
    NEUROPEDIATRICS, 2003, 34 (03) : 120 - 126
  • [4] Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis
    Salama, HH
    Hong, J
    Zang, YCQ
    El-Mongui, A
    Zhang, JW
    BRAIN, 2003, 126 : 2638 - 2647
  • [5] Glatiramer acetate for multiple sclerosis
    La Mantia, Loredana
    Munari, Luca M.
    Lovati, Roberta
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (05):
  • [6] Mechanism of action of glatiramer acetate in treatment of multiple sclerosis
    Weber, Martin S.
    Hohlfeld, Reinhard
    Zamvil, Scott S.
    NEUROTHERAPEUTICS, 2007, 4 (04) : 647 - 653
  • [7] Spasticity in multiple sclerosis and role of glatiramer acetate treatment
    Eustasio Meca-Lallana, Jose
    Hernandez-Clares, Rocio
    Carreon-Guarnizo, Ester
    BRAIN AND BEHAVIOR, 2015, 5 (09):
  • [8] Mechanism of action of glatiramer acetate in treatment of multiple sclerosis
    Martin S. Weber
    Reinhard Hohlfeld
    Scott S. Zamvil
    Neurotherapeutics, 2007, 4 : 647 - 653
  • [9] The role of glatiramer acetate in the early treatment of multiple sclerosis
    Brandes, David W.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 329 - 336
  • [10] Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
    Taskapilioglu, Ozlem
    Turan, Asli Bahar
    Albas, Murat
    Turan, Omer Faruk
    TURKISH JOURNAL OF NEUROLOGY, 2012, 18 (01) : 17 - 20